Clinical Trial Update: Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated long-term immune responses and safety of GSK's herpes zoster vaccine in healthy adults. Results were posted after study completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• GSK Herpes Zoster Vaccine (recombinant zoster vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 2 | Status: COMPLETED | Results posted: 2017-10-05